Abstract
Late-life depression (LLD) is a major depressive disorder that affects someone after the age of 60 years. LLD is frequently associated with inadequate response and remission from antidepressants, in addition to polypharmacy. Pharmacogenetics offers a promising approach to improve clinical outcomes in LLD via new discoveries determining the genetic basis of response rates and side effects, as well as the development of tailored pharmacogenetic-based decision support tools. This invited review evaluates the LLD pharmacogenetic evidence base and the extent to which this was incorporated into existing commercial decision support tools and clinical pharmacogenetic guidelines.
Original language | English |
---|---|
Pages (from-to) | 1269-1284 |
Number of pages | 16 |
Journal | Pharmacogenomics |
Volume | 19 |
Issue number | 16 |
DOIs | |
State | Published - Nov 2018 |
Keywords
- decision support tools
- late-life depression
- major depression
- pharmacogenomics
- precision medicine